Clinical Trials Sponsored by Accuray Incorporated

Total 1198 results

Vertex Pharmaceuticals Incorporated

Active, not recruiting

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study To Evaluate the Relative Bioavailability, Food Effect, and Dose Proportionality of a Granule Formulation of Vanzacaftor/Tezacaftor/Deutivacaftor(VNZ/TEZ/D-IVA)

Cystic Fibrosis

United States
Bausch & Lomb Incorporated

Completed

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

Allergic Conjunctivitis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Relative Bioavailability and Food Effect of a VX-118 Tablet Formulation

Cystic Fibrosis

United States
Bausch & Lomb Incorporated

Completed

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

Cataract

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF Genotypes

Cystic Fibrosis

Canada, France, United Kingdom, Israel, Australia, Spain, Germany, Netherlands, Denmark, Switzerland
Cook Group Incorporated

Completed

Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses (XPEDITE)

Peripheral Arterial Disease (PAD)

Germany, New Zealand
Bausch & Lomb Incorporated

Completed

Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.

Allergic Conjunctivitis

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older

Cystic Fibrosis

United States, Canada, Australia, Ireland, United Kingdom
Vertex Pharmaceuticals Incorporated

Completed

A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Effect of Food on the Pharmacokinetics of VX-548

Pain

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

Diabetic Peripheral Neuropathy

United States
Vertex Pharmaceuticals Incorporated

Completed

Evaluation of the Effects of Omeprazole and Rifampin on the Pharmacokinetics of VX-548 in Healthy Participants

Pain

Australia
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of Different Add Powers With a New Presbyopic Lasik Treatment Algorithm

Ametropia

Philippines
Vertex Pharmaceuticals Incorporated

Completed

Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Belgium, Netherlands, United Kingdom, Australia, France, Denmark, Germany, Italy, Canada
Vertex Pharmaceuticals Incorporated

Completed

A Study to Evaluate the Safety of Long-term Ivacaftor Treatment in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age at Treatment Initiation and Have an Approved Ivacaftor-Responsive Mutation

Cystic Fibrosis

United States, Canada, Australia, Ireland, Germany, United Kingdom
Bausch & Lomb Incorporated

Completed

Orientation Characteristics of Kalifilcon A Daily Disposable Toric Contact Lenses Compared to Acuvue Oasys 1-Day for Astigmatism Contact Lenses

Astigmatism

United States
Sound Pharmaceuticals, Incorporated

Enrolling by invitation

SPI-1005 Treatment in Moderate COVID-19 Patients

Coronavirus Infection | Covid19 | Corona Virus Infection | Coronavirus

United States
Vertex Pharmaceuticals Incorporated

Completed

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

Cystic Fibrosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)

Cystic Fibrosis

Spain, Belgium, Australia, Canada, Czechia
Vertex Pharmaceuticals Incorporated

Completed

Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Glomerulosclerosis, Focal Segmental

United States, France, United Kingdom, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Long-term Safety of VX-445 Combination Therapy

Cystic Fibrosis

United States, Spain, Ireland, Israel, Australia, United Kingdom, Germany, Canada, Denmark, Poland, Switzerland
Cook Group Incorporated

Completed

Evaluation of the Zilver Vascular Stent in the Iliac Arteries (ZIPS)

Peripheral Arterial Disease (PAD)
Bausch & Lomb Incorporated

Completed

Therapeutic Equivalence Study of Generic Brinzolamide vs Azopt

Glaucoma | Open Angle or Ocular Hypertension

United States
Aspen Global Incorporated

Terminated

Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban (HITSOVA)

Heparin-induced Thrombocytopenia

United States, Bosnia and Herzegovina, Canada, France, Germany, Italy, Poland, Russian Federation, Serbia
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating Efficacy and Safety of VX-548 for Acute Pain After an Abdominoplasty

Acute Pain

United States
Bausch & Lomb Incorporated

Completed

1-Week Dispensing Evaluation of Kalifilcon A Toric Contact Lenses Compared to Ultra for Astigmatism

Astigmatism | Myopia

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study to Explore the Impact of Lumacaftor/Ivacaftor on Disease Progression in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del

Cystic Fibrosis

Germany
Cook Group Incorporated

Completed

Removal of the Evolution® Esophageal Stent - Fully Covered (CLARITY)

Esophageal Neoplasms | Stents | Esophageal Perforation | Esophageal Fistula | Esophageal Stenosis

United States
Vertex Pharmaceuticals Incorporated

Completed

A Dose-ranging Study to Evaluate Efficacy and Safety of VX-150 in Subjects With Acute Pain Following Bunionectomy

Acute Pain

United States
Bausch & Lomb Incorporated

Completed

Insertion Clinical Study to Evaluate the Aberration Characteristics of Kalifilcon A Toric Lenses

Contact Lens Wearer

United States
Spherix Incorporated
BioSpherix

Terminated

Therapeutic Gaming for the Treatment of Attention Deficit Hyperactivity Disorder (THERAGAME)

Attention Deficit Hyperactivity Disorder
Bausch & Lomb Incorporated

Completed

Product Performance of a New Silicone Hydrogel Contact Lens

Myopia

United States
Vertex Pharmaceuticals Incorporated

Completed

A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Israel, Ireland, United Kingdom
Bausch & Lomb Incorporated

Completed

LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Pain | Ocular Inflammation | Cataract

United States
Bausch & Lomb Incorporated

Completed

Clinical Study of Approved Contact Lenses

Myopia

United States
Vertex Pharmaceuticals Incorporated

Completed

Observational Study of Outcomes in Cystic Fibrosis Patients With Selected Gating Mutations on a CFTR Allele (The VOCAL Study) (VOCAL)

Cystic Fibrosis

Netherlands, Italy, United Kingdom
Bausch & Lomb Incorporated

Completed

A Study to Evaluate the Performance of Two Designs of Soft Toric Lenses

Myopia

United States
Bausch & Lomb Incorporated

Completed

Evaluation of Two Different Designs of Bausch & Lomb Contact Lenses

Myopia

United States
Bausch & Lomb Incorporated

Completed

Bepotastine Besilate Nasal Sprays in the Treatment of Seasonal Allergic Rhinitis (SAR)

Seasonal Allergic Rhinitis

United States
Vertex Pharmaceuticals Incorporated

Terminated

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Pancreatic Cancer

United States
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Bausch & Lomb Incorporated

Completed

Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism

Astigmatism

United States
Bausch & Lomb Incorporated

Completed

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Bausch & Lomb Incorporated

Completed

Safety and Efficacy of Bepotastine Besilate Ophthalmic Solution in Seasonal Allergic Conjunctivitis Patients

Allergic Conjunctivitis

United States
Bausch & Lomb Incorporated

Completed

A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease

Dry Eye Syndrome

United States
Bausch & Lomb Incorporated

Completed

Mapracorat Ophthalmic Formulation in Subjects With Allergic Conjunctivitis

Conjunctivitis, Allergic

United States
Bausch & Lomb Incorporated

Terminated

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation Following Cataract Surgery

Pain | Inflammation | Cataract

United States
Bausch & Lomb Incorporated

Completed

Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Inflammation | Cataract | Surgery

United States
Vertex Pharmaceuticals Incorporated

Terminated

Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

Cystic Fibrosis

United States

3

Subscribe